ProShare Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-25,509
| Closed | -$514K | – | 2361 |
|
|
2021
Q3 | $514K | Sell |
25,509
-6,171
| -19% | -$170K | ﹤0.01% | 1201 |
|
|
2021
Q2 | $1.18M | Buy |
31,680
+3,497
| +12% | +$107K | ﹤0.01% | 940 |
|
|
2021
Q1 | $721K | Buy |
28,183
+1,989
| +8% | +$50.8K | ﹤0.01% | 1195 |
|
|
2020
Q4 | $577K | Buy |
26,194
+6,232
| +31% | +$137K | ﹤0.01% | 1170 |
|
|
2020
Q3 | $359K | Sell |
19,962
-679
| -3% | -$14.1K | ﹤0.01% | 1078 |
|
|
2020
Q2 | $524K | Buy |
20,641
+8,094
| +65% | +$174K | ﹤0.01% | 933 |
|
|
2020
Q1 | $230K | Sell |
12,547
-9,270
| -42% | -$180K | ﹤0.01% | 961 |
|
|
2019
Q4 | $481K | Sell |
21,817
-2,589
| -11% | -$52.1K | ﹤0.01% | 1073 |
|
|
2019
Q3 | $350K | Sell |
24,406
-1,267
| -5% | -$18.1K | ﹤0.01% | 1145 |
|
|
2019
Q2 | $404K | Sell |
25,673
-1,483
| -5% | -$20.2K | ﹤0.01% | 1102 |
|
|
2019
Q1 | $398K | Buy |
27,156
+229
| +0.9% | +$2.63K | ﹤0.01% | 1125 |
|
|
2018
Q4 | $288K | Buy |
+26,927
| New | +$354K | ﹤0.01% | 1181 |
|
|
2016
Q4 | – | Sell |
-13,089
| Closed | -$77K | – | 1761 |
|
|
2016
Q3 | $77K | Sell |
13,089
-2,339
| -15% | -$8.2K | ﹤0.01% | 1427 |
|
|
2016
Q2 | $46K | Sell |
15,428
-1,555
| -9% | -$6.39K | ﹤0.01% | 1555 |
|
|
2016
Q1 | $91K | Sell |
16,983
-1,777
| -9% | -$11.2K | ﹤0.01% | 1526 |
|
|
2015
Q4 | $223K | Buy |
+18,760
| New | +$215K | ﹤0.01% | 1479 |
|
Other funds holding DRNA
ProShare Advisors's DRNA Position: Q4 2021 in Review
ProShare Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 25,509 shares — an estimated $514K sold.
ProShare Advisors first reported a position in DRNA in Q4 2015 and held it in 16 quarters. The position peaked at $1.18M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- ProShare Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- ProShare Advisors sold 25,509 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $514K.
- ProShare Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2015 and held it in 16 quarters.
- ProShare Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $1.18M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.